Are natural killer cells superior CAR drivers?

Oncoimmunology. 2014 Apr 15;3:e28147. doi: 10.4161/onci.28147. eCollection 2014.

Abstract

T lymphocytes engineered to express a chimeric antigen receptor (CAR) are being celebrated as a major breakthrough of anticancer immunotherapy. Natural killer cells have not received similar attention as CAR effectors, although the use of these relatively short-lived cytotoxic cells is associated with several advantages.

Keywords: CAR; NK cells; NK-92 cells; T lymphocytes; cancer; on-target/off-tumor effect.